Celularity Inc., a biopharmaceutical company, develops placental-derived off-the-shelf therapeutic and cellular medicines for cancer, infectious diseases, and degenerative diseases. The company offers Biovance, a human amniotic membrane allograft that provides a protective cover and supports the body's wound healing processes; and Interfyl, a connective tissue matrix for various surgical applications when there is a need to replace and supplement damaged or inadequate integumental tissue. It also offers allogeneic placenta-derived cell therapy product candidates. The company was incorporated in 2016 and is based in Florham Park, New Jersey.
Часто задаваемые вопросы
В каком секторе работает GX Acquisition Corp (GXGX)?
GX Acquisition Corp относится к сектору Финансы.
Выплачивает ли GX Acquisition Corp (GXGX) дивиденды?
Нет, GX Acquisition Corp не выплачивает дивиденды.